Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2016

Stover Elizabeth H, Konstantinopoulos Panagiotis A, Matulonis Ursula A, Swisher Elizabeth M

Abstract excerpt

Drugs targeting DNA damage repair (DDR) pathways are exciting new agents in cancer therapy. Many of these drugs exhibit synthetic lethality with defects in DNA repair in cancer cells. For example, ovarian cancers with impaired homologous recombination DNA repair show increased sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors. Understanding the activity of different DNA repair pathways in individual...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Repair

Share to Drug Resistance, Neoplasm

Share to ATM gene

Share to ATR gene

Share to Mutation

Share to Neoplasms

Source

Identifiers

PMID: 27678458
DOI: 10.1158/1078-0432.CCR-16-0247

Genes

ATM
ATR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.PMID 27678458Read ↗

Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors.Semantic proximity Read ↗

Therapeutic Targeting of DNA Damage Response in CancerSemantic proximity Read ↗

Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis and TreatmentSemantic proximity Read ↗

DNA Damage Response in Cancer Therapy and Resistance: Challenges and OpportunitiesSemantic proximity Read ↗

Advancing cancer therapy: new frontiers in targeting DNA damage responseSemantic proximity Read ↗

Biomarkers for chemotherapy and drug resistance in the mismatch repair pathwaySemantic proximity Read ↗

Clinical assays for assessment of homologous recombination DNA repair deficiency.Semantic proximity Read ↗

Biomarkers for Homologous Recombination Deficiency in CancerSemantic proximity Read ↗

Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.Semantic proximity Read ↗

Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer TherapySemantic proximity Read ↗

Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic ApproachesSemantic proximity Read ↗

DNA Damage and Repair Biomarkers of Immunotherapy ResponseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.